Kenzik KM, et al. - The authors reviewed older patients with chronic myelogenous leukemia (CML) for their Medicare spending and patient spending over the first 5 years from the time of CML diagnosis in the tyrosine kinase inhibitor (TKI) era. From the Surveillance, Epidemiology, and End Results–Medicare database, researchers identified medicare beneficiaries with CML who were diagnosed between 2007 and 2012 at age > 65 years (805 beneficiaries) and frequency-matched a noncancer Medicare beneficiary sample based on age, sex, and race/ethnicity (805 individuals). The analysis revealed comparable 5-year survival rates of older patients with CML with adequate time receiving TKI therapy to those of their counterparts without cancer. However, significant Medicare and patient spending were evident in correlation to TKI use; patients receiving multiple TKIs (ie, dasatinib or nilotinib along with imatinib) constitute the group with the highest spending.